Abstract
Epidemiological studies have suggested that obstructive sleep apnea syndrome (OSAS) may increase the risk of developing cognitive impairment. In patients with Alzheimer’s disease (AD), the prevalence of OSAS is much higher than that expected in cognitively healthy subjects. A deeper knowledge of the pathophysiological link between OSAS and AD and the demonstration that OSAS may directly influence the development of cognitive alterations, would increase prevention and treatment strategies for AD patients. In this article, we discuss the evidence of the association between OSAS and dementia. Moreover, we present data about the functional and anatomic cerebral changes induced by OSAS and the possible effects on cognitive activities and on AD pathogenesis. The possibility to positively influence cognitive impairment by OSAS treatment will be also discussed.
Keywords: Alzheimer’s disease, cognitive deterioration, continuous positive airway pressure, obstructive sleep apnea syndrome, pathophysiology, preventive strategies.
Graphical Abstract
CNS & Neurological Disorders - Drug Targets
Title:Obstructive Sleep Apnea Syndrome: An Emerging Risk Factor for Dementia
Volume: 15 Issue: 6
Author(s): Laura Buratti, Simona Luzzi, Cristina Petrelli, Sara Baldinelli, Giovanna Viticchi, Leandro Provinciali, Claudia Altamura, Fabrizio Vernieri and Mauro Silvestrini
Affiliation:
Keywords: Alzheimer’s disease, cognitive deterioration, continuous positive airway pressure, obstructive sleep apnea syndrome, pathophysiology, preventive strategies.
Abstract: Epidemiological studies have suggested that obstructive sleep apnea syndrome (OSAS) may increase the risk of developing cognitive impairment. In patients with Alzheimer’s disease (AD), the prevalence of OSAS is much higher than that expected in cognitively healthy subjects. A deeper knowledge of the pathophysiological link between OSAS and AD and the demonstration that OSAS may directly influence the development of cognitive alterations, would increase prevention and treatment strategies for AD patients. In this article, we discuss the evidence of the association between OSAS and dementia. Moreover, we present data about the functional and anatomic cerebral changes induced by OSAS and the possible effects on cognitive activities and on AD pathogenesis. The possibility to positively influence cognitive impairment by OSAS treatment will be also discussed.
Export Options
About this article
Cite this article as:
Buratti Laura, Luzzi Simona, Petrelli Cristina, Baldinelli Sara, Viticchi Giovanna, Provinciali Leandro, Altamura Claudia, Vernieri Fabrizio and Silvestrini Mauro, Obstructive Sleep Apnea Syndrome: An Emerging Risk Factor for Dementia, CNS & Neurological Disorders - Drug Targets 2016; 15 (6) . https://dx.doi.org/10.2174/1871527315666160518123930
DOI https://dx.doi.org/10.2174/1871527315666160518123930 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sugars that Glow in the Dark: Fluorescent Tagged Glucose Bioprobes and their Facilitation of the Drug Discovery Process
Current Medicinal Chemistry Diabetes Mellitus to Neurodegenerative Disorders: Is Oxidative Stress Fueling the Flame?
CNS & Neurological Disorders - Drug Targets TREM2 and the Progression of Alzheimer’s Disease
Current Neurovascular Research Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the treatment of Alzheimer’s Disease
Current Neuropharmacology Relationship Between the Chemokine Receptor CCR5 and Microglia in Neurological Disorders: Consequences of Targeting CCR5 on Neuroinflammation, Neuronal Death and Regeneration in a Model of Epilepsy
CNS & Neurological Disorders - Drug Targets Anticancer Agents: VTA or VDA
Current Bioactive Compounds Enhancement of Delayed Audiovisual Response in Parkinson’s Disease: A Comparison with Normal Aged Controls
Neuroscience and Biomedical Engineering (Discontinued) Chloride Channels − New Targets for the Prevention of Stroke
Current Vascular Pharmacology Amelioration of Dementia and Antioxidant Activity of <i>Holarrhena antidysenterica</i> Bark in Mice
Current Psychopharmacology Herbal Insomnia Medications that Target GABAergic Systems: A Review of the Psychopharmacological Evidence
Current Neuropharmacology The Expanding Universe of Neurotrophic Factors: Therapeutic Potential in Aging and Age-Associated Disorders
Current Pharmaceutical Design Fenofibrate, Homocysteine and Renal Function
Current Vascular Pharmacology Fluoride Interactions: From Molecules to Disease
Current Signal Transduction Therapy Neuronal and Glial Responses to Polyamines in the Ischemic Brain
Current Neurovascular Research Cardiovascular Complications of HIV Infection and Treatment
Cardiovascular & Hematological Agents in Medicinal Chemistry Antagonism of Endothelin (ETA and ETB) Receptors During Renovascular Hypertension-Induced Vascular Dementia Improves Cognition
Current Neurovascular Research Hypoxia Inducible Factor-1 as a Target for Neurodegenerative Diseases
Current Medicinal Chemistry Reduction of β-Amyloid Accumulation by Reticulon 3 in Transgenic Mice
Current Alzheimer Research Treating Alzheimers Disease by Inactivating Bioactive Amyloid β Peptide
Current Alzheimer Research Neurodegeneration and Neurogenesis: Focus on Alzheimers Disease
Current Alzheimer Research